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 Glycogen	   is	   a	   polymer	   of	   glucose	   and	   serves	   as	   a	   source	   of	   rapidly	   available	   energy.	  Glycogen	  synthesis	  is	  initiated	  by	  autoglucosylation	  of	  glycogenin.	  Two	  glycogenin	  genes,	  
GYG1	  and	  GYG2,	  encode	  the	  two	  isoforms	  glycogenin-­‐1	  and	  -­‐2,	  respectively.	  Glycogenin-­‐1	   is	   ubiquitously	   expressed	   whereas	   glycogenin-­‐2	   has	   been	   described	   as	   being	  expressed	  mainly	  in	  the	  liver	  but	  also	  in	  the	  heart.	  	  This	   thesis	  describes	   two	  new	  disorders	  affecting	  glycogen	   turnover.	  The	   first	  disease	  presented	   as	   sudden	   cardiac	   arrest	   due	   to	   arrhythmia	   after	   exercise	   in	   a	   27-­‐year-­‐old	  man.	  Clinical	  history	  revealed	  minor	  muscle	  weakness	  of	  the	  upper	  extremities.	  He	  was	  found	   to	   have	   a	   cardiomyopathy	   with	   abnormal	   glycogen	   storage	   in	   the	   heart	   and	  depletion	  of	   glycogen	   in	   the	   skeletal	  muscle.	  An	   amino	  acid	   substitution	  was	  detected	  from	   a	   threonine	   to	   a	   methionine	   at	   position	   83	   of	   glycogenin-­‐1	   that	   resulted	   in	  inactivated	  autoglucosylation.	  Detailed	  studies	  applying	  cell-­‐free	  protein	  expression,	   in	  
vitro	   glucosylation,	   and	   mass	   spectrometry	   (MS)	   demonstrated	   abolished	   Tyr-­‐O-­‐glucosylation,	  the	  initial	  step	  of	  the	  autoglucosylation.	  Catalytically	  active	  glycogenin-­‐1,	  but	  not	  glycogenin-­‐2,	  could	  compensate	  for	  this	  defect	  by	  inter-­‐molecular	  glucosylation.	  Transcriptome	   and	   western	   blot	   analyses	   indicated	   that	   glycogenin-­‐2	   is	   mainly	  expressed	  in	  liver	  and	  adipose	  tissue	  and	  only	  to	  a	  minor	  degree	  in	  cardiac	  and	  skeletal	  muscle.	  By	  applying	  a	  automated	  analysis	  of	  glycopeptides	  from	  MS	  data	  of	  co-­‐expressed	  glycogenin-­‐1	   and	   -­‐2,	   we	   show	   that	   glycogenin-­‐1	   enhances	   the	   glucosylation	   of	  glycogenin-­‐2.	  	  The	   second	   disease	   presented	   as	   myopathy	   and	   cardiomyopathy	   in	   10	   patients	   from	  eight	  families.	  Initial	  symptoms	  were	  leg	  weakness	  starting	  in	  childhood	  or	  adolescence,	  later	   followed	   by	   generalized	   muscle	   weakness	   and	   cardiomyopathy.	   The	  cardiomyopathy	  was	  rapidly	  progressive,	  necessitating	  heart	  transplantation	  in	  several	  cases.	  The	  characteristic	  morphological	  features	  were	  inclusions	  of	  abnormal	  glycogen,	  polyglucosan,	  in	  approximately	  50%	  of	  the	  skeletal	  muscle	  fibers	  that	  were	  depleted	  of	  normal	   glycogen.	   Different	   truncating	   and	   missense	   mutations	   were	   detected	   in	   the	  gene	   RBCK1,	   coding	   for	   an	   E3	   ubiquitin	   ligase.	   RBCK1	   deficiency	   appears	   to	   be	   a	  common	  type	  of	  glycogen	  storage	  disease	  and	  is	  to	  be	  considered	  in	  cases	  with	  dilated	  cardiomyopathy.	  	  In	   conclusion,	   we	   have	   described	   two	   new	   glycogenoses	   affecting	   heart	   and	   skeletal	  muscle	  and	   investigated	   the	  pathogenesis.	  The	  discovery	  of	   the	  genetic	  background	  of	  these	  novel	  disease	  entities	   is	   important	  for	  correct	  diagnosis,	  evaluation	  of	  prognosis,	  genetic	  counseling	  and	  treatment.	  	  Keyword:	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